ABSTRACT
Background Understanding the mechanisms underlying disease progression in Multiple Sclerosis (MS) is fundamental to pave the way to treatment advances. Smoldering demyelinating inflammation characterized by iron deposition is observed at the edges of chronic active lesions and represents a relevant substrate of disease progression in MS. However, the influence of genetic factors on these mechanisms is not known. Leveraging the importance of iron deposition in smoldering inflammation, we assessed whether variants in genes belonging to iron-related pathways affect disease progression in MS.
Methods We investigated the association between Single Nucleotide Polymorphisms (SNPs) mapping to 334 genes in iron-related pathways and the risk of disease progression, studying 2,817 MS patients from Italy (n=755) and Sweden (n=2,062), and comparing relapsing-remitting (RR-MS) with secondary progressive (SP-MS) disease course. To better understand the link of the identified variant with smoldering inflammation, we applied a multilayered approach using independent cohorts from Italy, Sweden and the United Kingdom and encompassing gene expression, PRL analysis, neurofilament levels, post-mortem spinal cord pathology and pharmacogenomics.
Results We found an association between a locus in the Hypoxia-Inducible Factor 1-alpha (HIF1A) gene and the odds of SP-MS transition in the Italian cohort (rs11621525; SP-MS OR 0.57, 95% CI 0.44-0.72; P=3.30×10-6), which was replicated in the Swedish dataset (rs1951795; OR 0.79, 95% CI 0.67-0.95; P=0.0079). Additional analyses showed that patients carrying the protective allele exhibited reduced HIF1A expression in the immune cells, lower PRL volume, lower plasma/cerebrospinal fluid neurofilament levels, and lower inflammation and acute axonal injury in the post-mortem spinal cord. Moreover, the variant influenced the response to dimethyl fumarate, an approved MS drug with effect on mechanisms shared with HIF1A pathway.
Conclusion A novel locus in the HIF1A gene, a crucial hub for iron-binding capacity, inflammation, and hypoxia response, is associated with the risk of disease progression in MS. Converging lines of evidence support the role of this locus in smoldering inflammation, prompting future studies to explore the potential of HIF1A as a therapeutic target in progressive MS.
Competing Interest Statement
AG, PS, MP, MS, EM, SS, KM, FC, MN, MC, TM, KS, RO, ES, AH, SBK, and KA: nothing to disclose. PP reports compensation for speaking activity from Bristol Myers Squibb, Sanofi Genzyme, Novartis, Roche, Merck. LF received intellectual property interests from a discovery or technology relating to health care. AM reports compensation for consulting services from Biogen and for speaking activity from Biogen, research support from Karolinska Institutet. FP reports compensation for participation in advisory boards from Parexel/Chugai, Swedish Medical Products Agency, research support from UCB, Merck. LA reports research support from AFA insurance, Swedish Research Council, Swedish Brain Foundation, Region Stockholm. JH reports compensation for participation in advisory boards from Biogen, Celgene, Merck, Novartis, Sandoz, Sanofi, research support from Biogen, Celgene, Merck, Novartis, Sanofi, and Roche. TO reports compensation for participation in advisory boards from Biogen, Novartis, Merck, Sanofi, research support from Biogen, Novartis, Sanofi, Merck. TG reports research support from Karolinska Institutet, Region Stockholm, Merck, Swedish Society for Medical Research. MJ reports research support from Swedish Research Council, EU Horizon, European Research Council (ERC-CoG). GCD reports compensation for consulting services from Neurology Academy, for speaking activity from Merck, Roche, research support from NIHR, BRC (Oxford), National Health and Medical Research (Australia), UK MS Society, Oxford-Quinnipiac Partnership, US Department of Defense, Wellcome ISSF, Bristol Myers Squibb, University of Oxford (John Fell Fund), for serving as an editorial board member for MS Journal. MR received consulting fees from Biogen, Bristol-Myers Squibb, Eli Lilly, Janssen, and Roche; speaker honoraria from AstraZeneca, Biogen, Bristol-Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck-Serono, Novartis, Roche, Sanofi, and Teva Pharmaceuticals; and research support from the Multiple Sclerosis Society of Canada, the Italian Ministry of Health, and Fondazione Italiana Sclerosi Multipla. MF reports compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, and Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and Teva; participation in advisory boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, and Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Eli Lilly, Novartis, and Sanofi-Genzyme; and research support from Biogen Idec, Merck-Serono, Novartis, Roche, Italian Ministry of Health, and Fondazione Italiana Sclerosi Multipla. IK reports compensation for speaking activity from Merck, research support from Swedish Research Council, National MS society, EU Horizon 2020. FE reports compensation for consulting services from Merck, Novartis, for participation in advisory boards from Novartis, Merck, research support from Italian MS Society, Italian Ministry of Health, ERA Net, European Commission. FE has received intellectual property interests from a discovery or technology relating to health care.
Funding Statement
This study was supported by ERA PerMed-JTC2018 (co-funded by the European Commission) and the European Union in the Horizon 2020 Framework Programme for Research and Innovation (2014-2020). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of IRCCS San Raffaele Scientific Institute, Karolinska Institutet and Oxford Neuroinflammation Center gave ethical approval for this work. Approval numbers are as follows. IRCCS San Raffaele Scientific Institute: 1013/DG, 274/DG, 397/ER/mm, 851/DG, 20/int/2019. Karolinska Institutet: 02-548, 2006/845-31/1, 2009/2107-31/2. 2011/641-31/4, 02-548, 2015/2235-32/4, 2015/2236-32, 2015/2260-32/2, 2016/1167-32, 2016/1168-32, 2016/1169-32, 2017/1347-32, 2017/1348-32, 2017/1349-32, 2017/1350-32, 2017/1426-32. Oxford Neuroinflammation Center: REC-08/MRE09/31+5.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.